Torbjørn Bjerke
Founder chez Arctic Asset Management AS (Sweden)
Fortune : 679 183 $ au 31/03/2024
Profil
Torbjørn Bjerke is the founder of Arctic Asset Management AS (Sweden) in 2016, TXP Pharma GmbH in 2014, and Action Pharma A in 2000.
He is currently the Chairman of TXP Pharma AG (Switzerland), Director of Biothea Pharma, Inc., and Portfolio Manager at Arctic Funds Plc - Aurora LifeScience since 2016.
Dr. Bjerke's former positions include Chief Executive Officer of Karolinska Development AB from 2011 to 2014, President & Chief Executive Officer of Biolipox AB from 2004 to 2007, and Chief Executive Officer of SynAct Pharma AB from 2016 to 2024.
He also served as Chairman, President & Chief Executive Officer of Orexo AB from 2007 to 2011.
Dr. Bjerke has held various director positions in companies such as Pergamum AB, NeoDynamics AB, KDev Investments AB, Axela AB, AstraZeneca AB, Aprea Therapeutics AB, Topotarget A, Palette Life Sciences AB, and Action Pharma Holding.
I A.
He was an Independent Director of DBV Technologies SA from 2006 to 2021 and an Independent Director of NTG Nordic Transport Group A from 2006 to 2013.
Dr. Bjerke's education includes a doctorate from the University of Aarhus.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
SYNACT PHARMA AB
2,36% | 20/06/2023 | 840 532 ( 2,36% ) | 679 183 $ | 31/03/2024 |
Postes actifs de Torbjørn Bjerke
Sociétés | Poste | Début |
---|---|---|
Arctic Asset Management AS (Sweden)
Arctic Asset Management AS (Sweden) Investment ManagersFinance Arctic Asset Management AS (Sweden) (AAM-Sweden) is the Sweden-based investment management arm of Arctic Asset Management AS, ultimately owned by Arctic Securities AS in Norway. The firm was founded in 2016 and is headquartered in Stockholm. AFM-Sweden manages portfolio of Nordic equities, Nordic fixed income and Global Life Science – through mutual funds and discretionary mandates for institutional clients, family offices, investment companies and private clients. | Founder | 01/01/2016 |
Arctic Funds Plc - Aurora LifeScience | Corporate Officer/Principal | 01/01/2016 |
Biothea Pharma, Inc.
Biothea Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Biothea Pharma, Inc. is an American biotechnology company that operates in the field of pharmaceuticals. The private company was founded by John F. Vavricka. Marina S. Bozilenko has been the CEO of the company since 2021. | Director/Board Member | - |
TXP Pharma AG (Switzerland)
TXP Pharma AG (Switzerland) Pharmaceuticals: MajorHealth Technology Part of SynAct Pharma AB, TXP Pharma AG (Switzerland) engages in researching and developing pharmaceutical drugs for the treatment of autoimmune and inflammatory diseases. The private company is based in Baar, Switzerland. TXP Pharma AG (Switzerland was acquired by SynAct Pharma AB from GoodWind Holding GmbH on January 16, 2023 for $264.94 million. | Chairman | - |
Anciens postes connus de Torbjørn Bjerke
Sociétés | Poste | Fin |
---|---|---|
SYNACT PHARMA AB | Chief Executive Officer | 20/03/2024 |
DBV TECHNOLOGIES | Director/Board Member | 19/05/2021 |
Karolinska Development AB (Private Equity)
Karolinska Development AB (Private Equity) Investment ManagersFinance Karolinska Development AB (Private Equity) (Karolinska Development) is a Venture Capital firm, a subsidiary of Karolinska Development AB founded in 2003. The firm is headquartered in Solna. | Chief Executive Officer | 31/10/2014 |
KAROLINSKA DEVELOPMENT AB | Chief Executive Officer | 30/09/2014 |
NTG NORDIC TRANSPORT GROUP A/S | Director/Board Member | 30/11/2013 |
Formation de Torbjørn Bjerke
University of Aarhus | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 7 |
---|---|
NTG NORDIC TRANSPORT GROUP A/S | Transportation |
ALK-ABELLÓ A/S | Health Technology |
OREXO AB | Health Technology |
DBV TECHNOLOGIES | Health Technology |
NEOS AB | Health Technology |
KAROLINSKA DEVELOPMENT AB | Finance |
SYNACT PHARMA AB | Health Technology |
Entreprise privées | 19 |
---|---|
Arctic Funds Plc - Aurora LifeScience | Miscellaneous |
AstraZeneca AB
AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Commercial Services |
Topotarget A/S
Topotarget A/S Pharmaceuticals: MajorHealth Technology Topotarget A/S is a biotechnology company that is engaged in the development and commercialization of novel drugs for the treatment of cancer. Its product belinostat is a novel histone deacetylase inhibitor which is used for cancer patients. The company was founded by Peter Buhl Jensen and Maxwell Sehested in 2000 and is headquartered in Copenhagen, Denmark. | Health Technology |
Karolinska Development AB (Private Equity)
Karolinska Development AB (Private Equity) Investment ManagersFinance Karolinska Development AB (Private Equity) (Karolinska Development) is a Venture Capital firm, a subsidiary of Karolinska Development AB founded in 2003. The firm is headquartered in Solna. | Finance |
Biolipox AB
Biolipox AB Pharmaceuticals: MajorHealth Technology Biolipox AB develops and manufactures pharmaceuticals products. The company engages in the research and development of pharmaceuticals for the treatment of respiratory and other inflammatory diseases such as asthma, chronic obstructive pulmonary disease, rhinitis, pain, and arthritis. It was founded in June 2000 and is headquartered in Solna, Sweden. | Health Technology |
Action Pharma A/S
Action Pharma A/S BiotechnologyHealth Technology Action Pharma A/S is an R&D-focused biotech company located in the Nordic Medicon Valley area in Copenhagen, Denmark. Action Pharma was founded in 2000 and has a pipeline of 4 drug candidates in different stages of development, plus additional compounds in discovery and early preclinical development. Action Pharma pursues the discovery and development of new drugs and treatment concepts to treat cardiovascular diseases, inflammatory diseases and metabolic diseases, such as type-II diabetes and obesity. Its drug candidates are modified endogenous peptides with improved efficacy and small chemical entities targeted the melanocortin receptors. In disease models, its drug candidates have shown strong effects in treating and preventing inflammation and organ damage in conditions such as post-surgical organ dysfunction and acute myocardial infarction. A major focus for Action Pharma is treatment candidates for type-II diabetes, obesity and metabolic syndrome. Moreover, several drug candidates have shown effects in treating inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis and dermatitis. | Health Technology |
Aprea Therapeutics AB
Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Health Technology |
Axelar AB
Axelar AB BiotechnologyHealth Technology Axelar AB operates as a biotechnology company. It aims to develop novel efficacious anti-cancer treatments. The company was founded by Erik Gustav Magnus Axelson and Lars Olov Larsson in 2003 and is headquartered in Solna, Sweden. | Health Technology |
Pergamum AB
Pergamum AB Pharmaceuticals: MajorHealth Technology Pergamum AB develops, registers, markets, and trades pharmaceutical products based on therapeutic peptides. The company was founded on June 18, 2008 and is headquartered in Solna, Sweden. | Health Technology |
Action Pharma Holding I A/S | |
TBIOTECH ApS | |
Selskabet af 20.02.2002 ApS | |
Palette Life Sciences AB
Palette Life Sciences AB Medical SpecialtiesHealth Technology Palette Life Sciences AB operates as a pharmaceutical company. It specializes in developing products for local pain relief in obstetrics and gynecology. The company was founded by Berith Karlsson Tingåker, Gunvor Ekman-Ordeberg, Arne Folke Brodin and Lars Irestedt in 2009 and is headquartered in Solna, Sweden. | Health Technology |
Axela AB | |
KDev Investments AB
KDev Investments AB BiotechnologyHealth Technology KDev Investments AB engages in research, sales, and development in the fields of medicine, biotechnology, pharmaceuticals, and medical technology. It also owns and manages investments of companies in the fields of medicine. Its portfolio will include both early and clinical stage pharmaceutical assets, as well as some technology assets. The company was founded on January 10, 2012 and is headquartered in Solna, Sweden. | Health Technology |
Arctic Asset Management AS (Sweden)
Arctic Asset Management AS (Sweden) Investment ManagersFinance Arctic Asset Management AS (Sweden) (AAM-Sweden) is the Sweden-based investment management arm of Arctic Asset Management AS, ultimately owned by Arctic Securities AS in Norway. The firm was founded in 2016 and is headquartered in Stockholm. AFM-Sweden manages portfolio of Nordic equities, Nordic fixed income and Global Life Science – through mutual funds and discretionary mandates for institutional clients, family offices, investment companies and private clients. | Finance |
Biothea Pharma, Inc.
Biothea Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Biothea Pharma, Inc. is an American biotechnology company that operates in the field of pharmaceuticals. The private company was founded by John F. Vavricka. Marina S. Bozilenko has been the CEO of the company since 2021. | Commercial Services |
TXP Pharma AG (Switzerland)
TXP Pharma AG (Switzerland) Pharmaceuticals: MajorHealth Technology Part of SynAct Pharma AB, TXP Pharma AG (Switzerland) engages in researching and developing pharmaceutical drugs for the treatment of autoimmune and inflammatory diseases. The private company is based in Baar, Switzerland. TXP Pharma AG (Switzerland was acquired by SynAct Pharma AB from GoodWind Holding GmbH on January 16, 2023 for $264.94 million. | Health Technology |
TXP Pharma GmbH |